Literature DB >> 17407037

Outcomes attributable to neonatal candidiasis.

Theoklis E Zaoutis1, Kateri Heydon, Russell Localio, Thomas J Walsh, Chris Feudtner.   

Abstract

BACKGROUND: The incidence of candidiasis has increased in neonatal intensive care units, and invasive candidiasis is associated with significant morbidity and mortality. However, few data exist on outcomes directly attributable to neonatal candidiasis.
METHODS: We estimated the incidence of systemic candidiasis in hospitalized neonates within the United States and determined the attributable mortality, length of hospital stay, and associated costs. We used the 2003 Kid's Inpatient Database from the Healthcare Cost and Utilization Project. Systemic candidiasis and comorbidities were defined by International Classification of Diseases, Ninth Revision, Clinical Modification codes. Neonates with uncomplicated births and neonates who died within the first 3 days of life were excluded. We used propensity score methods to balance covariates between the neonates with and neonates without candidiasis. Attributable outcomes were calculated between propensity score-matched neonates with and neonates without candidiasis. Because of the known confounding effect of birth weight, we performed separate propensity score analyses for extremely low birth weight (ELBW) neonates (i.e., neonates weighing < 1000 g).
RESULTS: The overall incidence of invasive candidiasis in neonates is 15 cases per 10,000 neonatal admissions (95% confidence interval [CI], 13-16 cases per 10,000 neonatal admissions). ELBW neonates with invasive candidiasis were 2 times more likely to die (odds ratio, 2.2; 95% CI, 1.4-3.5) than propensity-matched ELBW neonates without candidiasis. The propensity score-adjusted mortality rate attributable to candidiasis among ELBW neonates was 11.9%. Candidiasis in ELBW infants was not associated with an increase in length of hospital stay but was associated with a mean increase in total charges of $39,045 (95% CI, $1374-$76,715). Among infants with a birth weight > or = 1000 g, those who had candidiasis did not experience a significant increase in mortality, compared with infants without candidiasis. However, the propensity score-adjusted length of stay and charges attributable to candidiasis among neonates with a birth weight > or = 1000 g were 16 days (95% CI, 8-24 days) and $122,302 (95% CI, $80,457-$164,148), respectively.
CONCLUSIONS: Invasive candidiasis is associated with a significantly increased risk of death and excess hospital charges in ELBW neonates and with excess hospital stay and excess hospital charges in neonates with a birth weight > or = 1000 g.

Entities:  

Mesh:

Year:  2007        PMID: 17407037     DOI: 10.1086/513196

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN: 1058-4838            Impact factor:   9.079


  16 in total

1.  Erythematous plaques and papules on a premature infant.

Authors:  Kelsie Riemenschneider; Rachel Redenius; Jeff Reese; Jo-David Fine; Joern-Hendrik Weitkamp; Eric Tkaczyk
Journal:  J Am Acad Dermatol       Date:  2017-04       Impact factor: 11.527

Review 2.  Emerging drugs and vaccines for candidemia.

Authors:  Brad Moriyama; Lori A Gordon; Matthew McCarthy; Stacey A Henning; Thomas J Walsh; Scott R Penzak
Journal:  Mycoses       Date:  2014-10-08       Impact factor: 4.377

3.  Systemic antifungal prescribing in neonates and children: outcomes from the Antibiotic Resistance and Prescribing in European Children (ARPEC) Study.

Authors:  J M Lestner; A Versporten; K Doerholt; A Warris; E Roilides; M Sharland; J Bielicki; H Goossens
Journal:  Antimicrob Agents Chemother       Date:  2014-11-17       Impact factor: 5.191

4.  Trends in Infantile Endogenous Endophthalmitis Hospitalizations in the United States: An Analysis from 2007 through 2014 Using the National Inpatient Sample.

Authors:  Chandana Papudesu; Tahreem Mir; Wei Fang; Jesse Thompson; David M Hinkle
Journal:  Ophthalmol Retina       Date:  2020-05-06

5.  Fungemia by Candida pelliculosa (Pichia anomala) in a neonatal intensive care unit: a possible clonal origin.

Authors:  Carolina Maria da Silva; Ana Maria Rabelo de Carvalho Parahym; Mariele Porto Carneiro Leão; Neiva Tinti de Oliveira; Rosemary de Jesus Machado Amorim; Rejane Pereira Neves
Journal:  Mycopathologia       Date:  2012-12-12       Impact factor: 2.574

6.  Pediatric antifungal utilization: new drugs, new trends.

Authors:  Priya A Prasad; Susan E Coffin; Kateri H Leckerman; Thomas J Walsh; Theoklis E Zaoutis
Journal:  Pediatr Infect Dis J       Date:  2008-12       Impact factor: 2.129

7.  Risk factors for invasive candidiasis in infants >1500 g birth weight.

Authors:  Jan Hau Lee; Christoph P Hornik; Daniel K Benjamin; Amy H Herring; Reese H Clark; Michael Cohen-Wolkowiez; P Brian Smith
Journal:  Pediatr Infect Dis J       Date:  2013-03       Impact factor: 2.129

8.  Potentiation of azole antifungals by 2-adamantanamine.

Authors:  Michael D Lafleur; Lingmei Sun; Ida Lister; John Keating; Andre Nantel; Lisa Long; Mahmoud Ghannoum; Jeffrey North; Richard E Lee; Ken Coleman; Thomas Dahl; Kim Lewis
Journal:  Antimicrob Agents Chemother       Date:  2013-05-20       Impact factor: 5.191

9.  Antifungal activity of 25-azalanosterol against Candida species.

Authors:  J Wang; J Wu
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2008-06-24       Impact factor: 3.267

10.  Clinical Practice Guideline for the Management of Candidiasis: 2016 Update by the Infectious Diseases Society of America.

Authors:  Peter G Pappas; Carol A Kauffman; David R Andes; Cornelius J Clancy; Kieren A Marr; Luis Ostrosky-Zeichner; Annette C Reboli; Mindy G Schuster; Jose A Vazquez; Thomas J Walsh; Theoklis E Zaoutis; Jack D Sobel
Journal:  Clin Infect Dis       Date:  2015-12-16       Impact factor: 9.079

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.